Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Last Updated: May 29, 2023

Details for Patent: 7,671,032

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,671,032 protect, and when does it expire?

Patent 7,671,032 protects OLYSIO and is included in one NDA.

This patent has seventy-six patent family members in thirty-four countries.

Summary for Patent: 7,671,032
Title:HCV NS-3 serine protease inhibitors
Abstract: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. ##STR00001##
Inventor(s): Rosenquist; Asa (Huddinge, SE), Thorstensson; Fredrik (Linkoping, SE), Johansson; Per-Ola (Linkoping, SE), Kvarnstrom; Ingemar (Linkoping, SE), Samuelsson; Bertil (Huddinge, SE), Wallberg; Hans (Huddinge, SE)
Assignee: Medivir AB (Huddinge, SE)
Application Number:10/572,349
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,671,032

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Prods OLYSIO simeprevir sodium CAPSULE;ORAL 205123-001 Nov 22, 2013 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,671,032

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0400199Jan 30, 2004
Sweden0401288May 19, 2004
Sweden0402562Oct 22, 2004
PCT Information
PCT FiledJanuary 28, 2005PCT Application Number:PCT/SE2005/000097
PCT Publication Date:August 11, 2005PCT Publication Number: WO2005/073195

International Family Members for US Patent 7,671,032

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047793 ⤷  Try a Trial
Argentina 048401 ⤷  Try a Trial
Argentina 104445 ⤷  Try a Trial
Austria 448243 ⤷  Try a Trial
Austria 461209 ⤷  Try a Trial
Australia 2005207815 ⤷  Try a Trial
Australia 2005207816 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.